GlycoMimetics, Inc.
9780 Medical Center Drive
Rockville
Maryland
20850
United States
291 articles about GlycoMimetics, Inc.
-
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
3/13/2024
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2023 full year financial results on Wednesday, March 27, 2024 at 8:30 a.m. ET.
-
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
2/26/2024
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that Harout Semerjian, Chief Executive Officer, will participate in the Leukemia Panel at the Cowen 44th Annual Health Care Conference in Boston, MA on Monday, March 4, 2024 at 12:50 p.m. ET.
-
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - February 12, 2024
2/12/2024
GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on February 6, 2024 of a non-qualified stock option award to purchase an aggregate of 130,000 shares of the Company’s common stock to Shantha Tyavanagimatt, Ph.D., the Company’s new Senior Vice President, Technical Operations.
-
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687
1/4/2024
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced positive initial safety, tolerability, and pharmacokinetic results from a Phase 1a study of GMI-1687 in healthy volunteers.
-
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia
12/10/2023
GlycoMimetics, Inc. announced the 65th American Society of Hematology Annual Meeting will feature two presentations on uproleselan, including an investigator-initiated trial studying the first-in-class E-selectin antagonist in patients with treated secondary Acute Myeloid Leukemia.
-
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference
11/9/2023
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference in London, UK on Thursday, November 16, 2023 at 1:30 p.m. GMT/8:30 a.m. ET.
-
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
11/3/2023
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the third quarter ended September 30, 2023.
-
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023
10/20/2023
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report third quarter 2023 financial results on Friday, November 3, 2023, at 8:30 a.m. ET.
-
GlycoMimetics Announces First Cohort Dosed in Human Phase 1a Study of GMI-1687
9/6/2023
GlycoMimetics, Inc. announced dosing of the first cohort of healthy volunteers in a Phase 1a study of GMI-1687 to evaluate safety, tolerability, and pharmacokinetics.
-
GlycoMimetics to Participate in Upcoming H.C. Wainwright 25th Annual Global Investment Conference
9/5/2023
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York, NY on Wednesday, September 13, 2023 at 11:30 a.m. ET.
-
GlycoMimetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - August 17, 2023
8/17/2023
GlycoMimetics, Inc. (the “Company”) (NASDAQ:GLYC) today announced that the Compensation Committee of the Company’s Board of Directors approved the grant on August 14 , 2023 of a non-qualified stock option award to purchase an aggregate of 110,000 shares to Gaetano Bonifacio, M.D., the Company’s new Vice President, Global Medical Affairs.
-
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
8/2/2023
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the second quarter ended June 30, 2023.
-
GlycoMimetics to Report Second Quarter 2023 Financial Results on August 2, 2023
7/19/2023
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report second quarter 2023 financial results on Wednesday, August 2, 2023, at 8:30 a.m. ET.
-
GlycoMimetics Announces Its Addition to the Russell Microcap® Index
6/26/2023
GlycoMimetics, Inc. today announced that it is set to join the Russell Microcap Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023.
-
GlycoMimetics Announces U.S. Food and Drug Administration Clears Addition of Time-based Final Analysis to Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory Acute Myeloid Leukemia
6/15/2023
GlycoMimetics, Inc. a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, announced the U.S. Food and Drug Administration cleared the addition of a protocol amendment to the company’s pivotal Phase 3 study of uproleselan for relapsed/refractory Acute Myeloid Leukemia.
-
GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference
5/31/2023
GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 7, 2023 at 4:00 p.m. ET.
-
GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023
5/3/2023
GlycoMimetics, Inc. today reported its financial results and highlights for the first quarter ended March 31, 2023.
-
GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023
4/26/2023
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2023 financial results on Wednesday, May 3, 2023, at 8:30 a.m. ET.
-
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2022
3/29/2023
GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2022.
-
GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023
3/16/2023
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth quarter and 2022 full year financial results on Wednesday, March 29, 2023, at 8:30 a.m. ET.